Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell lymphoma

Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell lymphoma. Jain N., Seghal L., Shuttleworth S.J., Samaniego F. Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2366.

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma. Huang S., Nastoupil L.J., Guo H., Bell T., Ahmed M., Li C.J., Wang J., Liu Y.,  Zhang V., Kim C.R., Boyle J.N., Lorence E.A., Lam L.T., Chen Z., Zhang H., Shuttleworth S.J., Nomie K., Wang M., Zhang L. Abstract 1837. 58th ASH Annual Meeting and […]

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (Mainz)

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finnemore D., Gatland A., Haque K., Lensun L., Roitt S., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J. Abstract 207. 14th CIMT Annual Meeting, Mainz, Germany, May 10-12, […]

KA2237 and KA2507. Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (New Orleans)

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Roitt S., Rogers H., Silva F.A., Ward P; Whale A., Shuttleworth S.J. In: Proceedings of the 107th Annual Meeting of […]

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Orlando)

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity. Alexander A., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J. 57th ASH Annual Meeting and Exposition, Orlando, […]

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Brussels)

Design and Development of a Novel PI3K-p110ß/d Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J. EORTC-NCI-EMA-AACR Conference on Innovation and Biomarkers in […]

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (Boston)

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity. Whale A.D., Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Shuttleworth S.J. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, […]

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy (Boston)

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy. Whale A.D., Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Shuttleworth S.J. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, […]

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy (New York)

Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque,K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J. CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference, New York City, September 18, 2015, Poster […]

Design and Development of a Novel PI3K-p110ß/δ Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity (New York)

Design and Development of a Novel PI3K-p110ß/d Inhibitor, KA2237 – Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J. CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference, New York City, September 18, […]